ReShape Lifesciences Q2 revenue down $0.6M YoY to $2.3M; operating expenses cut 53%

Vyome Holdings, Inc

2023-Q2 EPS reported -$2.48 revenue$4,541,000

Revenue $2.3M (-$0.6M vs Q2 2022); gross margin 53.0% vs 65.1%.
Non-GAAP adjusted EBITDA loss improved to $3.7M from $7.8M a year ago.
Cash $4.7M, debt-free; completed $2.5M registered direct offering in April.
Filed PMA supplement for Lap-Band 2.0; expects FDA feedback by year-end or early 2024.
Signed Hive preferred partner AI SMS platform; consultations up 107% at select accounts.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vyome Holdings, Inc reported financial results for the three and six months ended June 30, 2023.

Period: the three and six months ended June 30, 2023
Result: reported results

Exact text from the filing

On August 7, 2023, ReShape Lifesciences Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Vyome Holdings, Inc filing history →

Source: SEC EDGAR

accession 0001558370-23-013626

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.